Sorafenib tosylate novel drug delivery systems: Implications of nanotechnology in both approved and unapproved indications
The USFDA has approved sorafenib tosylate for the treatment of thyroid cancer, kidney cancer, and hepatocellular carcinoma. Conventional formulations of sorafenib tosylate have challenges of solubility, permeability, side effects, and drug resistance across cancer cells. Targeted cancer therapies ba...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , |
|---|---|
| Format: | Livre |
| Publié: |
Elsevier,
2022-11-01T00:00:00Z.
|
| Sujets: | |
| Accès en ligne: | Connect to this object online. |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_bd27e1049f554914bcd61dc18c58b097 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Hrushikesh Raut |e author |
| 700 | 1 | 0 | |a Chetana Jadhav |e author |
| 700 | 1 | 0 | |a Karishma Shetty |e author |
| 700 | 1 | 0 | |a Neha Laxane |e author |
| 700 | 1 | 0 | |a Harsh P. Nijhawan |e author |
| 700 | 1 | 0 | |a GSN Koteswara Rao |e author |
| 700 | 1 | 0 | |a Rajasekhar Reddy Alavala |e author |
| 700 | 1 | 0 | |a Garima Joshi |e author |
| 700 | 1 | 0 | |a Ch. Niranjan Patro |e author |
| 700 | 1 | 0 | |a Govind Soni |e author |
| 700 | 1 | 0 | |a Khushwant S. Yadav |e author |
| 245 | 0 | 0 | |a Sorafenib tosylate novel drug delivery systems: Implications of nanotechnology in both approved and unapproved indications |
| 260 | |b Elsevier, |c 2022-11-01T00:00:00Z. | ||
| 500 | |a 2352-9520 | ||
| 500 | |a 10.1016/j.onano.2022.100103 | ||
| 520 | |a The USFDA has approved sorafenib tosylate for the treatment of thyroid cancer, kidney cancer, and hepatocellular carcinoma. Conventional formulations of sorafenib tosylate have challenges of solubility, permeability, side effects, and drug resistance across cancer cells. Targeted cancer therapies based on nanotechnology have proven to be effective and have the potential to become a useful tool in these approved cancer indications. In addition, Sorafenib tosylate's novel formulations are also being investigated for the unapproved indications like hepatocellular cancer, renal cancer, and cholangiocarcinoma with promising outcomes. Nanotechnology-based formulations have shown considerable gains in bioavailability, absorption, and increased anticancer efficacy. The article reviews some of the relevant patents and clinical trials in this field. The article also assesses challenges associated and future prospects in designing such clinical ready novel formulations of sorafenib tosylate. | ||
| 546 | |a EN | ||
| 690 | |a Sorafenib Tosylate | ||
| 690 | |a Hepatocellular cancer | ||
| 690 | |a Renal cancer | ||
| 690 | |a Differentiated thyroid Cancer | ||
| 690 | |a Nano drug delivery system | ||
| 690 | |a Co-delivery | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n OpenNano, Vol 8, Iss , Pp 100103- (2022) | |
| 787 | 0 | |n http://www.sciencedirect.com/science/article/pii/S2352952022000652 | |
| 787 | 0 | |n https://doaj.org/toc/2352-9520 | |
| 856 | 4 | 1 | |u https://doaj.org/article/bd27e1049f554914bcd61dc18c58b097 |z Connect to this object online. |